Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED
精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

PLACING OF NEW SHARES UNDER GENERAL MANDATE
SUPPLEMENTAL ANNOUNCEMENT

Placing Agent

uSmart Securities Limited

Reference is made to the announcements of Extrawell Pharmaceutical Holdings Limited ("**Company**") dated 30 October 2026 and 5 November 2026 in relation to the proposed placing of new shares under general mandate ("**Announcements**"). Unless otherwise specified, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

As disclosed in the Announcements, completion of the Placing is conditional upon the fulfilment of the condition of the Placing Agreement by 13 November 2026 (or such later date as the Company and the Placing Agent may agree in writing) ("**Long Stop Date**"). As additional time is required for the Placing Agent to procure investors to subscribe for the Placing Shares, the Company and the Placing Agent, after arm's length negotiation, entered into a supplemental agreement ("**Supplemental Agreement**") to the Placing Agreement on 12 November 2026, pursuant to which the parties mutually agreed to amend the Long Stop Date to 20 November 2026 (or such later date as the Company and the Placing Agent may agree in writing).

Save and except for the aforesaid change, all other terms of the Placing Agreement remain unchanged and the Placing Agreement shall remain in full force and effect.

The Placing Price of HK$0.052 per Placing Share represents: (i) a discount of approximately 1.89% to the closing price of HK$0.053 per Share as quoted on the Stock Exchange on 12 November 2026, being the date of the Supplemental Agreement; and (ii) a premium of approximately 2.36% over the average closing price of approximately HK$0.0508 per Share as quoted on the Stock Exchange for the five consecutive trading days immediately prior to the date of the Supplemental Agreement.

Save and except for the aforesaid information, all other information contained in the Announcements remains unchanged.

WARNING

Since Completion is subject to the fulfilment of the condition as described in the Announcements, the Placing may or may not proceed. Shareholders and potential investors are reminded to exercise caution when dealing in the Shares.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 12 November 2026

As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Guo Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Wu Xiangyun, and the independent non-executive directors are Ms. Jin Song, Dr. Zeng Li and Ms. Yang Xiaorong.

* *For identification purpose only*